RxDoctor Payments Data

Serena Day, MD

Cardiovascular Disease · Mansfield, OHNPI 1669715348

Payments from drug & device makers

$575in general payments, 2019–2025

Across 12 payments — averaging $47.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mentor Worldwide LLC$125
  • Novo Nordisk$116
  • Edwards Lifesciences$102
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • E.r. Squibb & Sons, L.L.C.$50
  • AstraZeneca$30
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$45980%
  • Education$11620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575 in reported general payments places this provider in the 30th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$117,522
Medicare patients
1,182
Services billed
1,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban447$457,261
EntrestoSacubitril/Valsartan94$120,321
XareltoRivaroxaban60$98,809
JardianceEmpagliflozin57$51,445
Repatha SureclickEvolocumab27$23,988
FarxigaDapagliflozin Propanediol25$17,896
Praluent PenAlirocumab17$15,664
Metoprolol Succinate381$6,271
Ezetimibe139$4,814
Ranolazine ErRanolazine36$4,563
Atorvastatin Calcium345$3,263
Rosuvastatin Calcium222$2,959
ClopidogrelClopidogrel Bisulfate310$2,828
Carvedilol330$2,261
Isosorbide Mononitrate ErIsosorbide Mononitrate143$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$457,261447 claims
Boehringer IngelheimJardiance$15$51,44557 claims
AstraZenecaFarxiga$30$17,89625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →